Fidelity Investments
SKYE icon

Fidelity Investments’s Skye Bioscience SKYE Stock Holding History

Fidelity Investments’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-748
Closed -$561 – 5592
2025
Q4 		$561 Sell
748
-11,137
-94% -$16.3K ﹤0.01% 5144
2025
Q3 		$46.7K Hold
11,885
– – ﹤0.01% 4002
2025
Q2 		$49.7K Buy
11,885
+8,821
+288% +$18.3K ﹤0.01% 3910
2025
Q1 		$4.87K Buy
3,064
+913
+42% +$2.49K ﹤0.01% 4713
2024
Q4 		$6.09K Buy
2,151
+1,857
+632% +$7.76K ﹤0.01% 4622
2024
Q3 		$1.15K Buy
+294
New +$1.65K ﹤0.01% 4888

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's SKYE Position: Q1 2026 in Review

Fidelity Investments sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 748 shares — an estimated $561 sold.

Fidelity Investments first reported a position in SKYE in Q3 2024 and held it in 6 quarters. The position peaked at $49.7K in Q2 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Fidelity Investments reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 748 Skye Bioscience shares in Q1 2026, an estimated $561.
  • Fidelity Investments first reported a position in Skye Bioscience in Q3 2024 and held it in 6 quarters.
  • Fidelity Investments's Skye Bioscience position peaked at $49.7K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.